/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
, for a discussion of: Operations Principal Products Distribution and Customers Competition Regulatory Matters Research and Development Strategic Imperatives for 2026 We believe we have a significant opportunity to fundamentally transform how myopia and other refractive conditions are treated. We want to be the first choice for doctors and for patients seeking visual freedom from wearing eyegla…
$23.59
+$0.48 (+2.08%)
Live · 07:17 PM
The business is unprofitable at the operating level (-38.30% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 23.7% YoY. Margins deteriorated 34.3pp alongside, both lines moving the wrong way.
At 295x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from -2.32% to -17.70%, capital efficiency is deteriorating.
294.9x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$340M
▼ -23.7% YoY
Net Income (TTM)
$4M
▼ -298.1% YoY
Op. Margin
4.04%
▼ -34.3pp YoY
ROIC
2.77%
▼ -15.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$7M
▼ -422.2% YoY
Op. Cash Flow (TTM)
-$3M
▼ -317.7% YoY
Net Debt
-$146M
Net Cash Position
Cash & Equiv.
$181M
5Y CAGR: +7.9%
Continue Research
SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 3 Jul 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Price from market data, live as of 3 Sept 2026. Fiscal year ends Jan. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 294.9, Staar Surgical (STAA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Staar Surgical scores 28/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Staar Surgical scores 28 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 4.0% operating margin and a 2.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh STAA's valuation and scores 28/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.